Amanda Ricciuto

Amanda Ricciuto

Auto-generated profile, based on publicly available information

Amanda Ricciuto

Division of Gastroenterology, Hepatology & Nutrition, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
ARAmanda Ricciuto
Amanda Ricciuto
AGAnne M. Griffiths
Anne M. Griffiths
Inflammatory bowel disease (IBD) denotes a group of chronic incurable disorders characterized by relapsing-remitting inflammation of the gastrointestinal tract. IBD represents a growing global burden with a prevalence exceeding 0.3% in the Western world and an accelerating incidence in newly industrialized countries. The target for treating IBD has shifted in recent years from symptom control to mucosal healing (MH), which has been shown to be associated with favourable long-term outcomes. The gold standard for ascertaining MH is endoscopic assessment, but endoscopy is limited by its invasive nature, high cost and finite availability. Surrogate biomarkers are therefore of great utility. Calprotectin, a cytosolic protein derived predominantly from neutrophils, is now widely used in this capacity. Calprotectin is found in various bodily fluids at concentrations proportional to the degree of inflammation, including in feces at levels roughly six times higher than in the blood. Fecal calprotectin (FCP) therefore reflects intestinal inflammation. Various assays, including point-of-care and home-based tests, are now available for measuring FCP. FCP is used for screening purposes, to aid in distinguishing inflammatory from non-inflammatory gastrointestinal conditions like irritable bowel syndrome (IBS), as well as in the monitoring of known IBD. The aims of this review are to provide an overview of the methods used to measure FCP and to review the evidence supporting the use of FCP in IBD, particularly as it pertains to screening, monitoring and predicting disease relapse.

7 June 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
RLRebecca Little
Rebecca Little
EWEytan Wine
Eytan Wine
BKBinita M Kamath
Binita M Kamath
AGAnne M Griffiths
Anne M Griffiths
ARAmanda Ricciuto
Amanda Ricciuto
Gut microbiome in primary sclerosing cholangitis: A review

28 March 2018 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
ARAmanda Ricciuto
Amanda Ricciuto
BKBinita M. Kamath
Binita M. Kamath
AGAnne M. Griffiths
Anne M. Griffiths

17 March 2021 in Hepatology
Verified
Journal Article
Closed access
MDMark R. Deneau
Mark R. Deneau
CMCara Mack
Cara Mack
DMDouglas Mogul
Douglas Mogul
EPEmily R. Perito
Emily R. Perito
PVPamela L. Valentino
Pamela L. Valentino
SGStephen L. Guthery
Stephen L. Guthery

26 September 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
ARAmanda Ricciuto
Amanda Ricciuto
DMDavid R Mack
David R Mack
HHHien Q Huynh
Hien Q Huynh
KJKevan Jacobson
Kevan Jacobson
AOAnthony R Otley
Anthony R Otley
PCPeter C Church
Peter C Church
Background: Paediatric data on the association between diagnostic delay and inflammatory bowel disease [IBD] complications are lacking. We aimed to determine the effect of diagnostic delay on stricturing/fistulising complications, surgery, and growth impairment in a large paediatric cohort, and to identify predictors of diagnostic delay. Methods: We conducted a national, prospective, multicentre IBD inception cohort study including 1399 children. Diagnostic delay was defined as time from symptom onset to diagnosis >75th percentile. Multivariable proportional hazards [PH] regression was used to examine the association between diagnostic delay and stricturing/fistulising complications and surgery, and multivariable linear regression to examine the association between diagnostic delay and growth. Predictors of diagnostic delay were identified using Cox PH regression. Results: Overall (64% Crohn’s disease [CD]; 36% ulcerative colitis/IBD unclassified [UC/IBD-U]; 57% male]), median time to diagnosis was 4.2 (interquartile range [IQR] 2.0–9.2) months. For the overall cohort, diagnostic delay was >9.2 months; in CD, >10.8 months and in UC/IBD-U, >6.6 months. In CD, diagnostic delay was associated with a 2.5-fold higher rate of strictures/internal fistulae (hazard ratio [HR] 2.53, 95% confidence interval [CI] 1.41–4.56). Every additional month of diagnostic delay was associated with a decrease in height-for-age z-score of 0.013 standard deviations [95% CI 0.005–0.021]. Associations persisted after adjusting for disease location and therapy. No independent association was observed between diagnostic delay and surgery in CD or UC/IBD-U. Diagnostic delay was more common in CD, particularly small bowel CD. Abdominal pain, including isolated abdominal pain in CD, was associated with diagnostic delay. Conclusions: Diagnostic delay represents a risk factor for stricturing/internal fistulising complications and growth impairment in paediatric CD. Podcast: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast

3 March 2023 in Journal of Hepatology
Verified
Journal Article
Open access
ARAmanda Ricciuto
Amanda Ricciuto
BKBinita M. Kamath
Binita M. Kamath
GHGideon M. Hirschfield
Gideon M. Hirschfield
PTPalak J. Trivedi
Palak J. Trivedi
Autoimmune liver diseases are siloed into three syndromes that define clinical practice. These classifiers can, and are, challenged by variant presentations across all ages, something inevitable to disease definitions that rely on interpreting (inherently variable) semi-quantitative/qualitative clinical, laboratory, pathological or radiological findings. Furthermore this categorisation is premised on an ongoing absence of definable disease aetiologies. Clinicians thus encounter individuals with biochemical, serological, and histological manifestations that are common to both primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH), often labelled as 'PSC/AIH-overlap'. In childhood the term 'autoimmune sclerosing cholangitis (ASC)' may be used, and some propose this to be a distinct disease process. In this article we champion the concept that ASC and PSC/AIH-overlap are not distinct entities. Rather, they represent inflammatory phases of PSC frequently manifesting earlier in the disease course, most notably in younger patients. Ultimately, disease outcomes remain similar to those of a more classical PSC phenotype observed in later life. Thus, we argue that it is now time to align disease names and descriptions used by clinicians across all patient subpopulations, to help unify care. This will enhance collaborative studies and ultimately contribute to rational treatment advances.